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High blood pressure is the main risk factor worldwide for mortality and morbility. Subjects with 
uncontrolled hypertension increased in the last decades. This narrative review focused its attention 
on the diagnosis, the pathophysiology, the clinical consequences of arterial hypertension, and on the 
factors that must be considered for a better blood pressure control. Essential hypertension is caused 
by a complex interaction of genetic factors, modiulation of homeostatic systems, vessel wall 
modification, inflammatory mediators. The best therapeutic choice can be, in daily clinical practice, 
challenging due to the various classes of available drugs, the different individual responses to the 
same antihypertensive drug, the variability of the phenotypes. The review will also discuss the best 
strategy to reduce cardiovascular events in hypertensive patients targeting either the overall 
cardiovascular risk or to blood pressure levels only. This review is based on the material searched 
for and obtained via MEDLINE and PubMed up to March 2016. The search terms used were 
“hypertension, blood pressure control” in combination with “pathophysiology, lifestyle, arterial 
















Arterial hypertension (AH) represents the main risk factor worldwide for cardiovascular (CV) and 
all-cause mortality and is strongly correlated to the risk of stroke, myocardial infarction (MI), renal 
and heart failure [1]. AH prevalence increases with age involving one third of Western population 
and 70% of adults ≥ 70 years [2]. Further, despite a series of International Guidelines provides 
adequate support to the physicians, subjects with uncontrolled hypertension have been increasing 
over the last years [3-7]. This is in part due to population aging and to the increase in the prevalence 
of obesity [2]. Aim of this narrative review is therefore to begin with the pathogenetic mechanisms 
of AH, highlighting emerging issues such as arterial stiffness and inflammation , and understanding 
how can be individualized excellently antihypertensive therapy, providing a useful tool for the 
clinician to obtain the therapeutic goal. The control of BP also at a population level will be 
discussed. 
The Prospective Studies Collaboration (PSC) was a large meta-analysis of 61 observational studies 
on the association between BP and vascular mortality and performed between 1950 e 1990. It was 
based on 100,000 deaths among 1 million subjects without a history of vascular disease [8]. The 
main finding was a continuous log-linear association between BP and vascular mortality (coronary 
artery disease, stroke) irrespective of the baseline BP value, but with a diminishing association with 
aging: for every 20 mmHg lower systolic BP (SBP), the hazard ratio (HR) for death from CAD 
declined from 0.49 in subjects aged 40-49 to 0.67 in those aged 80-89 years [8]. The PSC and the 
Framingham Heart Study also showed that SBP was a stronger predictor of CV events (CVEs)  than 
diastolic BP (DBP)  [9]. About pulse pressure (PP) several data showed its predictive role of CVEs, 
particularly in elderly subjects [10]. Further, about BP as a predictor of CVEs all large 






Pathophysiology of hypertension 
Hypertension is a very complex disease with a multifactorial pathophysiology, which combine 
genetic factors, lifestyle, neuro-hormonal disorders, arterial stiffness, low-grade inflammation. In a 
simplified view, BP may be considered the product of cardiac output (CO) and peripheral resistance 
(PR). CO is the result of the fluid volume (preload) and the contractility of the heart. Hypertension 
occurred when CO and/or PR increased. The latter is a simplified version of the pathogenesis but 
also useful, as we described below, to understand its finer pathogenetic mechanisms. 
 
Genetic factors 
One of the aspects to investigate in hypertensive subjects is the presence of AH also in relatives. 
This fact confirm a genetic contribution to BP levels, with a role of multiple genes. Several studies 
found the presence of high BP as a part of family history in 60% of subjects [11]. In last years 
several studies investigated the presence of genetic polymorphism in human hypertension, also with 
the aim to predict the response to any given therapy. For example, Sciarrone [12] and co-workers 
showed that subjects with α-adducin Gly460→Trp polymorphism had a brilliant response to 
diuretic but not the other pharmacological classes. The International Consortium for Blood Pressure 
Genome – Wide Association Studies provided a genetic risk score based on 29 independent genetic 
variants. This score is associated with BP levels and TOD [13]. A very recent meta-analysis 
identified 34 genes associated to high BP levels [14]. Furthermore, some companies sell genetic test 
to identify individuals with genetic variants associated with, for example, an overactivation of the 
renin-angiotensin system (RAS) and that can consequently help in choosing the most suitable drug. 
However, today this is not applied in clinical practice because of the high costs. Currently, the 
research for hypertension genes is still developing and requires new and complex studies. The hope 





Lifestyle: sodium intake and obesity  
The sodium restriction in population is an important target for CV prevention, because sodium 
intake is positively associated with BP [16]. The mechanism involved many pathways, and has not 
been completely understood [17]. Certainly, a high sodium intake increases sodiemia and the 
subsequent volume-dependent BP level. Several studies analyze the sodium intake in different 
population across the world [18, 19]. The INTERrnational study of SALT and blood pressure 
(INTERSALT) studied salt intake in 52 population samples of 32 countries using 24-urinary 
specimens [18]. The 24-hour sodium excretion ranged from a minimum of 0,46 grams per day (g/d) 
in some remote population groups like Yanomami Indians to 5,6 g/d revealed in North China. The 
INTERrnational study of MAcro/micronutrients and blood Pressure (INTERMAP) confirmed these 
findings and underlined regional differences in sources of sodium intake: in the United Kingdom 
and in the United States the most dietary sodium comes from processed food, instead in China the 
principal source of sodium is the salt added to cooking [19].  
Many cohort studies reported a positive association between sodium intake and BP levels [20]. The 
Prospective Urban Rural Epidemiological (PURE) study showed an increase in SBP for each 1 g 
increase in sodium intake [20]. Furthermore, the increase in BP values varied depending on the 
baseline of sodium assumption. In accord with these findings, there was a reduction in SBP 
associated with a reduction in sodium intake, and this reduction was more significant in patients on 
high sodium diet [20]. Subjects can be divided in sodium sensitive, those who have with dietary 
sodium reduction a greater fall in BP, TOD and CVE, and sodium resistant. The first group 
presented low-renin levels, such as blacks or elderly subjects [21]. Many clinical trials evaluated the 
effect of sodium reduction on BP. One of the most noticeable, the Trial of HypertensiOn Prevention 
(THOP), conducted in North America, stressed the difficult to keep a low salt consumption and that 
over time there is an attenuation of the antihypertensive effect of sodium reduction [22]. However, 
several studies demonstrated the association between reduction in salt intake and incidence of CVEs 
and CV mortality. There is a large variability in results coming from prospective cohort studies, 
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ranged from a positive association between salt assumption and CVEs, null association and an 
inverse J-shaped association, with an increased risk in population with low sodium intake [23]. 
However, in Western population, sodium restriction is a key system for reducing BP levels and 
CVEs, without risk of J-shaped association because of the high content of sodium in processes food. 
Finally, authors suggest a target of sodium intake of 3-5 g/d. This is the range where subjects reach 
the better reduction of BP and the lowest rate of CVEs. The 24-hour sodium excretion is useful 
indicator of sodium intake: above 100 mmol per day indicate an excess of sodium intake. However, 
authors underlie that the key sources of excess sodium are processed food. The future of a correct 
sodium consumption is a process that involves food industry, which is the major responsible for the 
increase in sodium intake in Western populations. 
Excess weight gain is a major cause of AH and it is associated with CV and metabolic disease. 
Several studies conducted evidenced a linear association between BMI, and BP levels [24, 25]. The 
Framingham Offspring Study showed that overweight and obesity were responsible for 78% of 
essential hypertension in men and 65% in women [26].  Conversely, weight loss decreased BP 
levels [27]. Many factors influenced the relationship between obesity and AH. The BP control is 
much difficult the longer the duration of obesity. Another important aspect is the distribution of the 
fat. In fact, visceral and retroperitoneal fat are stronger associated with hypertension [28]. Although 
these clinical evidences, the pathophysiology of obesity-associated hypertension is not completely 
understood. Visceral adiposity determines a physical compression on the kidneys resulting in an 
increase in intrarenal pressure with an alteration of renal natriuresis [29]. Visceral obesity is also 
associated with a RAS iperactivation. Furthermore, in obese patients there is an increase in 
sympathetic activity and a decrease in parasympathetic tone [30, 31]. Finally, if overweight is 
maintained during several years, it can cause chronic kidney disease, which worsen hypertension 





The sympathetic Nervous System activaction 
The Sympathetic Nervous System (SNS) has an important role in the regulation of CV homeostasis. 
Several studies showed the association between SNS activation and increased resting heart rate and 
CV risk [34.]. Hypertensive subjects with a SNS overdrive presented a higher norepinephrine 
plasma concentration than normotensive subjects [35, 36]. Further, Mancia and co-workers with the 
norepinephrine spillover method, which involved the infusion of small doses of radiolabeled 
norepinephrine, demonstrated the increase in norepinephrine release from the adrenergic nerve 
terminals of these subjects [35, 36], and allowed to quantify the regional norepinephrine spillover, 
particularly in the heart and the kidney. Adrenergic mediators are also involved in arteriolar 
remodeling and are responsible of the increase in peripheral resistance [37, 38]. SNS overactivation 
is an early event in the history of AH, and may precede the hypertensive state [39]. In addition, the 
SNS overactivity is more frequent in young hypertensive subjects: this finding supports the concept 
that adrenergic overdrive may precede the development of the essential hypertension [35, 36]. 
Hypertensive patients with excessive TOD in relation to their BP levels and hypertension duration 
often showed a great sympathetic overdrive [40, 41], suggesting that an hyperadrenergic state may 
accelerate the progression of CVD.  
Based on the evidence discussed above, authors underlined that SNS overdrive has a role in the 
development, maintenance and progression of AH and could represent a primary target of 
pharmacologic and non-pharmacologic treatments. However, no clinical trial demonstrated the 
effect on mortality of decreasing adrenergic activity in AH [42]. 
 
The renin-angiotensin system 
In recent years, the central role of the RAS has been emphasized [43]. The excessive production of 
renin determines an overstimulation of AT1 receptors, resulting in hypertensive effects. The major 
action attributed to AT1 activation are vasoconstriction, increase of reactive oxygen species and 
activation of cytokines and growth factors (see below the section “Role of inflammation in 
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hypertension”) [43]. By contrast, AT2 receptors counteracted these effects [44]. To choose the best 
drug treatment, some authors suggest to subclassify subjects with AH in RAS-dependent essential 
hypertensive (high-normal renin levels) and volume-dependent hypertensive (low renin levels) [45]. 
The distinction between the two subtypes in clinical practice is not carried out by the dosage of 
renin levels  (which may depend on ongoing therapy or other factors), but on the basis of clinical 
features of the patient. Further, the dosage of renin in essential hypertension is not cost-
effectiveness and difficult in clinical practice [46]. However, RAS-dependent hypertension presents 
an increased sympathetic nervous system tone and is common in anxious young subjects or in 
people with a medical history of alcoholism, sleep apnea, acute stroke, sinus tachycardia, 
paroxysmal hypertension [45]. Mann and colleagues suggested in these subjects to add, if high BP 
levels are still present after a two drugs regimen (a traditional association RAS inhibitor + Anti-
volume), as third drug a beta-blocker or an alfa-blocker. Conversely, volume dependent 
hypertension is presented in subjects with high sodium intake, presence of edema, high body 
surface area, chronic kidney disease. In these subjects, these author suggested, in addition to the 
association RAS inhibitor + Anti-volume, to optimize the dose of the diuretic and eventually add as 
third drug spironolactone [45]. This mechanistic approach has not been transposed by International 
Guidelines but provides essential ideas at least for drug choice in the treatment of uncontrolled 
hypertension. In addition, Mann's point of view is useful to underline the importance of the 
activation of the RAS system in the pathogenesis of hypertension. 
 
Arterial stiffness and central BP: emerging factors to understand the pathogenesis of hypertension 
Arterial stiffness, which is emerging as a novel marker of subclinical arteriosclerosis, is expression 
of hardening (arteriosclerosis) of large arteries (primarily, aorta) due to abnormal collagen 
production and reduced amount of elastin, with consequent stiffening and thickening of the arterial 
wall [47, 48]. The gold standard to measure arterial stiffness is carotid-femoral pulse wave velocity 
(cfPWV), a noninvasive exam that measures aortic stiffness with applanation tonometry [49]. The 
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relationship between arterial stiffness and hypertension can be very complex: an increased baseline 
PWV is associated independently with disrupting effects on aortic elastin but, on the other hand, 
SBP increases aortic wall stress with an accelerated elastin degradation [50].  Although data from 
the Framingham Heart Study support the hypothesis that aortic stiffness may precede hypertension, 
other studies have found a relationship between baseline SBP and progression of PWV [51]. Since 
cfPWV increases with ageing and with higher BP levels, reference values were recently published 
[52]. The latest 2013 European Society of Cardiology (ESC)/European Society of Hypertension 
(ESH) guidelines for the management of Arterial Hypertension stressed the importance of cfPWV 
as a marker of subclinical vascular disease and confirmed a threshold value of 10 meter/second [3]. 
Many studies showed the independent role of cfPWV as a predictor of all-cause and CV mortality 
also in the general populations [53, 54]. Normally, aorta works as a diastolic pump which ensure a 
functioning tissue perfusion throughout the cardiac cycle. With stiffness, aorta lose its distensibility, 
and most of the stroke volume flows through the arterial system and peripheral tissue during 
systole. As a consequence, the flow becomes intermittent with excessive flow and pressure 
pulsatility during systole [55]. Further, in AH there are alterations also in small arteries: 
vasoconstriction, increased wall-to-lumen ratio and vessels rarefaction, with a consequent increase 
in total peripheral resistance and mean BP [56]. The final result is a large/small artery cross-talk: 
the higher mean BP increases large artery stiffness which leads to high central BP (CBP) and PP. 
As a vicious circle, the increased aortic stiffness in turn damages small resistance vessels [57]. With 
a heart beat a pulse wave travels forward in the circulation and generates multiple reflected waves 
which travel retrograde toward the heart. The composite reflected wave (sum of multiple tiny 
reflected waves) impacts the shape of the aortic pressure wave, which is the result of the sum of 
forward and backward wave. When PWV is elevated, the reflected wave return early in systole and 
CBP consequently increases [58]. As for cfPWV, even for CBP were validated reference values 
[59]. CBP seems to be a greater predictor of CVEs events than brachial pressure and some authors 
proposed the measure of CBP in clinical routine as a guide for therapeutic choice [60]. The Conduit 
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Artery Functional Evaluation (CAFE) Study first showed the clinical relevance of CBP: subjects 
randomized to calcium channel blocker (CCB) or to beta-blockers presented the same peripheral BP 
levels. By contrast, the first group showed a significant reduction in CBP and a significant less 
number of CVEs when compared to the second group (see also the below section “BP lowering 
drugs beyond BP targets and role for combination therapy”) [61]. In addition, if a large meta-
analysis [62] did not show a significant additive predictive value of CBP beyond brachial pressure 
(P = 0.057), other data demonstrated that the measure of CBP determines a better management of 
the hypertensive patient [63] and that CBP strongly correlated with TOD than brachial BP [64]. 
However, up to now, International Guidelines do not recommend routine CBP measurements in 
clinical daily practice [3, 4, 5, 6]. CBP could exert an important role in isolated systolic 
hypertension in youth, where an elevated PP amplification could lead to elevated brachial SBP with 
normal CBP. There is no evidence that these subjects could benefit of antihypertensive treatment 
[3]. 
 
Role of inflammation in hypertension 
Recent evidences stress the role of inflammation in hypertension [65]. As mentioned above, one of 
the effect of AT1 activation is the increase of inflammation with an excess of oxidative stress [65]. 
Several animal studies provided interesting data. The B7/CD28 T cell costimulation axis, which 
interacts with CD86 expressed on dendritic cells, is required for full activation of T lymphocytes 
[66]. The treatment of angiotensin II-induced hypertensive mice with an inhibitor of the axis 
lowered BP, and B7 deficient mice are resistant to BP elevation in response to angiotensin II [66]. 
Further, hypertensive mice presented an increased expression of CD86 in dendritic cells [67]. Other 
authors found in angiotensin II-induced hypertension an increased in aortic monocytes/macrophages 
and of markers inflammations such as vascular cell adhesion molecule-1, cyclooxygenase 2, nitric 
oxide synthase [68]. The accumulation of T cells and macrophages in experimental hypertension is 
predominant in the kidney and in the vessels, anatomic sites critical to the genesis and the 
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maintenance of AH [69]. Finally, emerging data showed also a role for neutrophils in hypertension 
[70]: very recently Liu and co-workers showed in a cohort of 28,850 adult Chinese subjects that 
elevated baseline neutrophil to lymphocyte ratio significantly increased the risk of developing 
hypertension [71].  
Figure 1 schematically summarize the pathogenesis of hypertension. 
 
Blood pressure measurement. Office values, home or ambulatory blood pressure monitoring: 
which is the best? 
One of the major topic discussed in hypertension research is the difference between the different 
methods for BP measurement. If International Guidelines continue to considered office BP 
measurements the gold standard for the diagnosis of AH [3, 4, 5, 6], several data and expert 
consensus provided interesting information on the important role of home BP and of ambulatory BP 
monitoring (ABPM), also for the prediction of CVEs [72]. In fact, ABPM can give information on 
the day/night BP cycle, the BP variability, the presence of white coat hypertension (WCH) or 
masked hypertension (MH) [72]. For these reasons, several trials such as the Systolic Hypertension 
in Europe (SYST-EUR) study [73], performed in patients with isolated systolic hypertension, the 
Dublin Outcome Study [74], and the Pressioni Associate Monitorate E Loro Associazioni 
(PAMELA) Study [75] showed that ABPM had a closer relation to CVEs than office BP values. 
About the day/night BP cycle, non-dippers subjects, probably for the more load of BP on the heart 
and the vessels, compared to dippers subjects, presented a more frequent occurrence of TOD and 
CVEs [75]. Further, Dublin Outcome Study and the PAMELA Study showed that the same increase 
in SBP values determined an increased CV mortality, when occurred during night, suggesting a 
superior prognostic role of absolute night-time BP values with respect to day-time BP values [74, 
75]. The risk increases even more in riser subjects: as the night-day ratio rises the CVEs increase. In 
extreme dipper subjects no sufficient data are available to determine a possible prognostic role [3].  
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BP variability, which increases with age and correlates with the mean BP level, depends on 
behavioural (for example, anxiety, job stress) and non-behavioural factors. Abnormal BP variability 
(in particular, nocturnal BP variability) is associated with presence of TOD and with an increased of 
CVEs and CV mortality [76]. The PAMELA study demonstrated that the short-term erratic or 
residual BP changes that contribute to overall 24-hours BP variability, in addition to its cyclic 
component (day-night and postprandial variations) have a significant relationship with CV and all-
cause mortality [75]. 
ABPM and home BP measurement are fundamental for the diagnosis of WCH and MH [77, 78]. 
WCH is a condition with a prognosis less worse than MH or sustained hypertension but that is 
important to diagnose and that should not be equated to the condition and the prognosis of 
normotensive subjects [75]. Both WCH and MH are associated with an increased metabolic risk 
such as diabetes and overweight and with an increased risk of TOD [77]. WCH has a prevalence of 
9-16% and is associated with age, female sex and non-smoking. Subjects with WCH presented an 
increased risk of developing sustained hypertension and a CV risk greater than normotensives [75]. 
MH has a prevalence of 13% and is associated with younger age, male sex, smoke, alcohol, 
physical activity, anxiety, job stress. Subjects with MH present an increases CV risk closer to that 
of sustained hypertension than to WCH or normotension [78]. 
Despite these observations, ESC/ESH Guidelines for the managemant of AH consider office BP the 
gold-standard for screening, diagnosis and management of hypertension and indicate the out-of-
office measurement in limited circumstances (for example, suspicion of WCH or MH, suspicious of 
true and false resistant hypertension) [3]. By contrast, the National Institute for Health and Clinical 
Excellence (NICE) guidelines suggests, if office BP is high, to offer ABPM to confirm the 
diagnosis of AH. Further, if a person is unable to tolerate ABPM, HBPM is a suitable method [5]. 
The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure 
Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension (CHEP) 
recommends for the diagnosis of hypertension office BP values ≥ 180 (SBP) and/or 110 mmHg 
13 
 
(DBP). Out-of-office BP measurements (if possible, ABPM) should be performed if in the first visit 
mean office BP measurement is 140-179 (SBP) mmHg and/or 90-109 mmHg (DBP) [6].  
Authors suggest, for the diagnosis and the management of AH, based on International Guidelines, 
expert consensus, cross-sectional and longitudinal studies, to add to office BP measurements at least 
home BP measurements. If there is the suspicious of abnormal night-time values or increased BP 
variability considering ABPM as soon as possible. However, it is also important to underlie that the 
reproducibility of ABPM is quite low, and one ABPM is not a sufficient to classify with certainty 
the night-time BP ratio and/or the BP variability of a subject [72]. 
 
Blood pressure lowering drugs: effects beyond target values and role for combination therapy 
RAS inhibitors are the recommended first-line drugs in Caucasian subjects [3]. Diuretics played a 
major role in Afro-American hypertensive subjects, because their AH is generally a volume-
dependent hypertension [4]. In elderly subjects with isolated systolic hypertension CCB and/or 
diuretic are the most effective in reducing SBP [3]. Beyond BP values, in the early 2000s, four trials 
provided the best evidence in favor of a particular drug-regimen: the Losartan Intervention For 
Event reduction Trial (the LIFE Trial) [79], the Valsartan Antihypertensive Long-term Use 
Evaluation trial (VALUE) [80], the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) [81] 
and the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with 
Systolic Hypertension trial (ACCOMPLISH) [82]. These trials showed a different number of CVEs 
in different drug-regimen groups despite no difference in brachial BP values between groups. In the 
LIFE Trial [79], 9,193 hypertensive patients were randomized to losartan or atenolol. 
Hydrochlorothiazide was added in the majority of patients to achieve BP control. After an average 
follow-up of 5 years the composite primary CV endpoint was reduced by 13% in the losartan group. 
The major benefit was seen in stroke which was reduced by 25%. In the VALUE trial [80], 15,245 
hypertensive patients were randomized to either valsartan, or amlodipine. Hydrochlorothiazide was 
added to each arm in attempting to achieve goal BP targets. Mean follow-up was 4.2 years. BP were 
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more effectively and more rapidly reduced in the amlodipine-based treatment arm. Although the 
primary composite endpoint of cardiac morbidity and mortality was similar in the two arms of the 
trial, MI and stroke occurred less frequently in the amlodipine-based treatment arm (risk reduction 
19% and 15%, respectively). In the ASCOT-BP trial [81], over 19,000 hypertensive patients with 
no prior history of CAD were randomized to amlodipine or atenolol. The ACE-Inhibitor perindopril 
or the diuretic bendroflumethiazide was added to each arm, respectively, in an attempt to achieve 
BP targets. After an average follow-up of 5.5 years, the trial was stopped prematurely because of 
highly significant outcome benefits in favor of the amlodipine-based regimen. All CVEs were 
reduced by 26%, stroke by 23%, and all-cause mortality by 11% by the amlodipine-based regimen. 
In the fourth  trial, ACCOMPLISH [82], 11,506 hypertensive patients were randomized to a 
combination of the benazepril, with either hydrochlorothiazide, or amlodipine. Patients were 
followed for 3 years. CVEs were reduced by 20% (MI by 22% and stroke by 16%, respectively) in 
benazepril/amlodipine arm compared with the benazepril/hydrochlorothiazide. These different in 
the primary outcomes are in part due to a better effect on CBP of a specific drug regimen, as the 
CAFE study (an ASCOT substudy) showed [61]. However, the cumulative evidence from these 
trials strongly supports the view that, in hypertensive patients, combination therapy with or 
ARB/CCB is likely to be associated with better CV outcomes and that ACE-I/CCB combinations 
are preferable to ACE-I/diuretic combinations on major CV endpoints. The above recommendations 
apply, in general, to those subjects with uncomplicated hypertension. In hypertensive subjects with 
associated CV disease such as heart failure or CAD, the guidelines are consistent in recommending 
specific drugs with compelling indications [83, 84]. 
In resistant hypertension, other trials showed that the addition of spironolactone to the association 
of RAS inhibitor + CCB + diuretic is more effective than the addition of an alpha-blocker or a beta-
blocker [85]. However, in all the cases of essential hypertension, several data suggested to start with 
a combination therapy [86]. The combination therapy provides an increased achieve of BP target, a 
synergistic effect of the drug combination, a reduction rate of side effects with also an increased 
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therapeutic adherence [3]. Further, in recent years a single pill contains two or three 
antihypertensive drug, with another reason of increased adherence in subjects in combination 
therapy [87]. A large meta-analysis [88] confirmed these considerations, and recently Gradman and 
co-workers showed the reduction rate in CVEs in subjects who started a combination therapy [89]. 
The reduction in CVEs was attributable to a more rapid achievement of target BP.  
The results of the main cited trials of this section are summarize in Table 1. 
 
Adherence to therapy and new treatments 
Non-adherence to therapy is one of the major cause of inadequate BP control in patients diagnosed 
with resistant hypertension [90]. The unrecognized of patients with falsely uncontrolled BP 
(pseudo-resistance) is very important. In fact, in case of noncompliance with the antihypertensive 
therapy clinician may requests additional expensive diagnostic test [91].  Furthermore, subjects poor 
concordant with therapy have an higher CV risk [92].  A recent meta-analysis reported a lower 
adherence in patients treated with diuretics and β-blockers [93]. Also the prescription of a large 
number of antihypertensive drugs is a possible cause for noncompliance [94]. Several methods have 
been suggested to evaluate the prevalence of non-adherence to treatment, including self-reporting 
questionnaires, electronic monitoring systems, pills counting and, in recent years, measurement of 
serum or urine drug concentration using liquid chromatography-mass spectrometry [95, 96]. Some 
of them, such as electronic records of pill box opening, do not prove the real drug intake and are 
less useful in clinical practice [97].  In a recent study [98] authors used the measurement of serum 
antihypertensive drug concentrations to test the concordance with treatment in two groups of 
patients diagnosed with resistant hypertension; the first group is composed of hospitalized patients, 
the second of outpatients. The non-adherence was surprisingly elevated, in particular in the second 
group in which accounted for almost 50%. Two other studies tested the adherence by toxicological 
urine analysis on samples collected on the day of the clinical visit [99, 100]. The complete non-
adherence was respectively of 30% and 25%. BP values were higher in nonadherent patients. Direct 
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urine or serum analysis have two important limitations: the technique in not available for all 
antihypertensive drugs and the method is relatively expensive (about 40-60 euro). However, 
investigations for secondary forms of hypertension or new interventional treatments have a greater 
cost. Lastly, even the noncompliance per se has a cost in terms of population’s health.  
For these reasons, physicians must have lot of attention to the problem of non-adherence, and it may 
be important to use motivational strategies such as involving patients in making decision, 
suggesting the use of HBPM, reducing the number of drugs with the single pill associations. 
Neprilysin, a neutral endopeptidase, degrades the brain natriuretic peptide (BNP), the urodilatin and 
the atrial natriuretic peptide (ANP). For these reasons, Neprilysin may be an important target in the 
treatment of AH [101]. Indeed neprilysin inhibition cause an increase in natriuretic peptides plasma 
levels and a subsequent vasodilation, natriuresis, reduction of adrenergic overdrive and of RAS 
activity, antiproliferative and antihypertrophic effects on vasculature and heart [102]. In AH 
treatment is useful to associate the neprilysin inhibitor with a RAS blocker or an endothelin-
converting enzyme inhibitor because neprilysin also degrades vasoconstrictor peptides. This 
association can lead to vasodilatation and natriuresis by reducing at the same time the 
vasoconstrictor effects [103]. LCZ696 is the first dual-acting agent composed of the association 
between neprilysin inhibitor prodrug AHU377 and valsartan. In a randomized, double-blind, 
placebo-controlled trial, LCZ696 was compared with valsartan and AHU377 in 1328 patients with 
mild to moderate hypertension. LCZ696 produced a significantly greater reduction in BP values 
than valsartan; AHU377 produced a BP reduction significantly greater than placebo but smaller than 
LCZ696. In the Phase III Prospective Comparison of angiotensin receptor-neprilysin inhibitor with 
ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) 
trial was compared the efficacy and safety of enalapril and LCZ696 in 8442 patients with class II, 
III or IV heart failure [104, 105]. This randomized double-blind trial underlined the superiority of 
LCZ696 in reducing BP, CV death and hospitalization. In the LCZ696 group there was also more 
reduction in mean SBP. The US Food and Drug Administration approved Entresto (Novartis), 
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sacubitril plus Valsartan, on July 2015 for the treatment of chronic heart failure [106].  
Catheter-based renal denervation (RDN) is an interventional treatment proposed for resistant 
hypertension, considering the role of SNS activity in elevation of BP [42]. In 2009, the 
nonrandomized study (Symplicity HTN-1) showed a significant reduction in BP after the RDN 
[107]. The following Symplicity HTN-2 confirmed these results [108]. The BP reduction was 
durable, lasting over 36 months of follow-up [109, 110]. However, these two trials had some 
limitations: they were not blinded (vulnerability to patient and physician related biases), and the 
evaluation of efficacy, was based on office rather than ABPM [111]. ABPM, as mentioned above, 
reduces observer bias and minimizes the white-coat effect. Further, drug adherence was not 
monitored, either at baseline or during follow-up. The subsequent Symplicity HTN-3 was a single-
blind randomized trial in order to prove the efficacy of the RDN in resistant hypertension [112]. 
Otherwise, Symplicity HTN-3 failed to reach the primary end point. Lack of demonstrated efficacy 
of RDN in Symplicity HTN-3 may be due to lack of statistical power or that the a fraction of 
African American participants increased their antihypertensive medication, contrary to protocol, 
which masked a potential BP lowering effect of RDN in contrast to other participants. In addition, 
as a consequence of the inexperience of the investigators,  the denervation procedure was inaccurate 
in many cases due to insufficient delivery of appropriate energy in the renal arteries. The Prague-15 
study was a very recent and rigorous study. This prospective, randomized, open-label multicenter 
trial evaluated the efficacy of RDN versus intensified pharmacological treatment including 
spironolactone in patients with true-resistant hypertension. This was confirmed by 24-hour ABPM 
after and by measurement of plasma antihypertensive drug levels. One-hundred six patients were 
randomized to renal denervation (n=52), or intensified pharmacological treatment (n=54). Both the 
arms of the study showed a significant and similar reduction in BP levels [113]. Further studies are 
needed to better understand the mechanism and the efficacy of renal denervation. 
The prospective non randomized DEBut-HT trial studied the early generation of implantable device 
for the electrical stimulation of the carotid sinus baroreceptors [114]. This trial studied 45 subjects 
18 
 
with resistant hypertension and showed a significant and prolonged reduction in office BP and in 
ABPM.  8 serious adverse events (7 procedure-related and 1 device-related) occurred. A second-
generation system of BAT (Barostim neo™) has been recently designed with the aim to reduce the 
operating field and hence possible complications. A single (instead of 5) electrode is implanted at 
one carotid site, and the battery is smaller, with an extended life span (≈3 years). In a single-arm 
open-label study enrolling 30 patients with resistant hypertension a significant BP reduction was 
observed after 6 months. Only 1 long-term procedure-related complications occurred [115]. Future 
studies will better clarify the role of stimulation of the carotid sinus baroreceptors in resistant 
hypertension. 
 
Blood pressure control: the earlier and the lower are the better? Importance of residual risk 
The management of hypertensive subject should be “BP oriented” or “risk factors oriented“? The 
treatment of the hypertensive patient should be modulated only according to BP levels or in relation 
to overall CV risk? International Guidelines for the management of AH appear to follow the first 
approach, providing BP thresholds (generally ≤ 140/90) that the patient must reach [3, 4, 5, 6]. 
However, guidelines for raised blood cholesterol suggest a “risk factors oriented“ approach, and the 
treatment is based on the overall CV risk, calculated, for example, with the European SCORE charts 
[116, 117]. Further, in their meta-analysis, the Blood Pressure Lowering Treatment Trialists’ 
(BPLTTC) conclude that the “risk factors oriented“ method based on CV risk calculators is more 
cost-effectiveness than the BP approach [118]. However, Zanchetti and co-workers, in a recent 
meta-analysis based on 68 randomized controlled trials, provided some interesting considerations 
[119]. As BPLTTC, they showed that relative reductions of all outcomes did not significantly differ 
in groups at different CV risk and absolute risk reductions significantly increased with the 
increasing level of CV risk, suggesting the cost-effectiveness of risk-based approach. However, key 
appears to emphasize that break down BP levels of high-risk individuals will not prevent the fact 
that these same individuals, because of their high residual risk, will present a larger number of 
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CVEs when compared to low-risk subjects [119]. This concept leads to make three important 
considerations. First, the best achievement in terms of prognosis is obtained by treating the subjects 
with mild hypertension without risk factors (“the earlier the better”). Second, at any level of CV 
risk, lower BP levels are better (“BP oriented” approach: the lower the better). Third, it is important 
to identify the residual risk of subjects by evaluating the presence of TOD to reclassify their CV 
risk and to modulate the drug therapy. Hence the importance of assess the presence of TOD in 
subjects with AH. The hypertensive patient should be evaluated for the presence of vascular organ 
damage (arterial stiffness), carotid damage (increased intima-media thickness (IMT, presence of 
atherosclerotic plaques), heart damage (left ventricular hypertrophy, systolic dysfunction, diastolic 
dysfunction, silent ischemia) [3]. However, these exams have costs and is a major challenge for the 
clinician to select patients for TOD evaluation. Recently, Struthers proposed the B-type natriuretic 
peptide (BNP) screening as a cost efficient system to identify hypertensive patients with residual 
risk [120]. The identification of patients with residual risk is important for drug regimen choice. For 
example, an hypertensive subjects without TOD can benefit (as mentioned in the above section) as a 
first-line drug of RAS inhibitor [3]. By contrast, the presence of a systolic dysfunction requires the 
addition of other drug classes such as beta-blockers [121]. 
Very recently, the Systolic blood PRessure INtervention Trial (SPRINT) convincingly support the 
concept “the lower the better”.  The SPRINT study randomized 9,361 hypertensive subjects with at 
least one CV risk factor (not diabetes) and older than 50 years to a “intensive” treatment group, 
designed to reach a SBP target < 120 mmHg, and a “protocol” group, designed to reach a SBP 
target < 140 mmHg. The study stopped early because of the superior benefits of the “intensive” 
treatment group on CVEs, CV mortality and total mortality, suggesting new SBP target, different 
from those proposed by International Guidelines [122, 123]. Several data of this study merit to be 
discussed. The results of SPRINT on “hard” endpoint could potentially change all the future 
Guidelines on AH. Heart failure was the most common CVE, and by contrast there was no 
difference between two groups on the incidence of stroke. This is in contrast with all the large 
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longitudinal trials on hypertension which have been demonstrated  that the strongest CV outcome 
related to hypertension is stroke. This could be attributable to the fact that the study stopped early, 
and some CVEs such as stroke have not had time to emerge. Hypotension, syncopal episodes, acute 
kidney injury, and serum electrolyte abnormalities were more commonly detected in the “intensive” 
treatment group, but certainly not so commonly as to cancel out the major observed benefits.  
The limitations of the study were the average run-in BP in SPRINT (averaging, 139.7 mm Hg), with 
a contingent modest BP fall to-target in the “intensive” treatment group (18 mm Hg) and the 
exclusion of diabetic and frail patients. For the same reasons this trial did not add knowledge about 
BP target to reach in high-risk individuals such as diabetics. The Action to Control Cardiovascular 
Risk in Diabetes Blood Pressure trial (ACCORD BP), which used the same SBP goals used in 
SPRINT to determine the value of intensive compared with standard BP reduction in 4,733 diabetic 
adults, showed that the composite CVD outcome was 12% lower in the intensive treatment group, 
but not statistically significant [124]. Another limitation of SPRINT is that the subjects enrolled in 
the study were more “fit” than those who, for example, live in nursing homes, so the trial did not 
provide information on BP thresholds in frail patients with lots of comorbidities [125]. Finally, 
although SPRINT results probably will radically change the future guidelines, this study has some 
severe limitations, and the clincian must individualize the BP goals taking into account all the 
patient’s characteristics.  
Finally, several studies have identified BP levels below which CVEs  increase rather than decrease. 
In the medical literature, this phenomenon has been called J curve: as above certain levels increase 
CVEs plungers, this also happens when BP is too low [126]. The attention was especially focused 
on DBP, the main factor underlying coronary perfusion. However lots of studies included subjects 
with CV disease, and some of these found a J-shaped curve also for DBP and stroke and for SBP 
and CAD [127]. In conclusion, up to date, down SBP values between 90 and 114 mmHg and DBP 
values between 60 to 74 mmHg there is no evidence to suggest a J-shaped. In conclusion, further 
studies, also performed in diabetic and in frail subjects, are needed to improve medical knowledge 
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on hypertension and definitel estabilished BP target values in different subgroups of hypertensive 
patients [127].  
The SPRINT and the ACCORD trials are summarize in Table 2. 
 
Blood pressure (un)control? Time for development of algorithms 
Despite the increased number of cross-sectional and longitudinal studies, International Guidelines 
and expert consensus paper, the majority of hypertensive subjects present uncontrolled hypertension 
[2]. As we mentioned in the introduction of this review, a critical role is probably attributable to 
population aging and to the increase in obesity. However, is important to stress some consideration. 
First, the National Health and Nutrition Evaluation Survey  (NHANES) showed that the overall 
prevalence of uncontrolled hypertension was 12.8%. Further, 81.5% of those with AH are aware 
they have it, and 74.9% are being treated. In addition, only 52.5% are under control, with significant 
variation across different patient subgroups [128]. Of those with uncontrolled hypertension, 89.4% 
reported having a usual source of healthcare, and 85.2% reported having health insurance. Second, 
the direct and indirect costs of AH are enormous, considering subjects and their families impacted 
and the healthcare money spent on treatment of BP complications [128]. Obtaining an adequate BP 
control at a population level has remained a challenge. Too often the healthcare provider, who  
visits of the hypertensive subjects, prescribe an inappropriate antihypertensive therapy. Too often, 
the hypertension specialist visits essential uncomplicated hypertensive subjects instead subjects 
with true resistant or secondary hypertension. It is time for an adequate hypertension knowledge at 
the level of community general medicine. To obtain this, system-level approaches and evidence-
based management algorithms can help to standardize the treatment. A virtuous example was the 
Kaiser Permanente Northern California, a regional American hypertension program which involved 
a population of 3 million subjects [129]. With a system-level method, this program provided an 
electronic hypertension registry, tracked hypertensive with regular feedback to providers, developed 
an evidence based algorithm, promoted single-pill combination therapy, used medical assistants for 
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follow-up BP checks. The result was a method that facilitates the physician in its therapeutic 
management and helped the patient in therapeutic adherence. Between 2001 and 2009 the number 
of subjects with AH increased by 100%, but hypertensive subjects meeting target BP goals 
improved from 44% to 80%, improved to more than 87% in 2011 [129]. Also the very recent 
SPRINT trial showed that a large number of subjects can reach the therapeutic target with treatment 
algorithms and careful monitoring, even with only two or three medicines (“control” and 
“intensive” group, respectively [122]. 
Also based on these data, the authors believe that the future of BP control will be based on a 
systematic approach with evidence based algorithms and a multifactorial coordination that help 
healthcare provider in the management of hypertensive subjects. The final step of an algorithm 
which provides simple and complete informations on AH management, in case the healthcare 
provider has properly executed all the algorithm steps but elevated BP levels perist, must be the 
visit of an hypertension specialist. In this way, the hypertension specialist would treat only patients 
with resistant or refractory hypertension, or, in any case, with BP levels complex to control. The 




Hypertension is the major risk factors in the world for CV and all-cause mortality. Further studies 
are needed to better understand its complex pathogenesis. The clinician to obtain a BP control for 
the individual patient should consider several factors such as age, lifestyle, the presence of other 
risk factors, presence of TOD. Further, recent data showed that start earlier and lower as soon as 
possible BP values reduce the risk. The combination therapy could be a good strategy to obtain this. 
Finally, a system level approach to the management of hypertension with the avoid of evidence 




Figure legend  
The pathogenesis of hypertension involves several factors such as genetic factors, inadequate 
lifestyle, SNS and RAS overactivation, inflammation, large artery stiffness, small vessels resistance 
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